Skip to content Skip to footer
Subscribe Now
NEWS

MAIA Biotechnology Reports P-II (THIO-101) Trial Data of Ateganosine Regimen for Advanced NSCLC

Shots: MAIA Biotechnology has reported P-II (THIO-101) trial data assessing ateganosine followed by  Libtayo (cemiplimab) in pts with advanced NSCLC who progressed after ≥2 SoC therapy regimens  As of Jun 30, 2025, ateganosine (180mg) showed mPFS of 5.6 vs 2.5mos. & mOS of 17.8mos., plus 2 pts completed 33 cycles across pts of all treatment lines,…
September 15, 2025

Read more

Ipo in Healthcare Top 20 2021
TOP 20

Top 20 IPOs in Healthcare by Total Fund Value

Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. Apart from the exposure and capital raise, companies gain more recognition, credibility, and indispensable value assessment 2022 had been a great year when it comes to the IPOs of healthcare companies. Bausch…
January 31, 2023

Read more